Assessment of Radiation-Induced Bladder and Bowel Cancer Risks after Conventionally and Hypo-Fractionated Radiotherapy for the Preoperative Management of Rectal Carcinoma.
IMRT
VMAT
bladder
bowel
hypo-fractionation
lifetime attributable risk
radiotherapy
rectal cancer
second cancer
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
31 Aug 2022
31 Aug 2022
Historique:
received:
31
07
2022
accepted:
29
08
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
24
9
2022
Statut:
epublish
Résumé
Preoperative management of rectal carcinoma can be performed by employing either conventionally or hypo-fractionated Radiotherapy (CFRT or HFRT, respectively), delivered by Intensity Modulated Radiotherapy (IMRT) or Volumetric Modulated Arc Therapy (VMAT) plans, employing 6 MV or 10 MV photon beams. This study aims to dosimetrically and radiobiologically compare all available approaches, with emphasis on the risk of radiation-induced second cancer to the bladder and bowel. Computed Tomography (CT) scans and relevant radiotherapy contours from 16 patients were anonymized and analyzed retrospectively. For each case, CFRT of 25 × 2 Gy and HFRT of 5 × 5 Gy were both considered. IMRT and VMAT plans using 6 MV and 10 MV photons were prepared. Plan optimization was performed, considering all clinically used plan quality indices and dose-volume constraints for the critical organs. Resulting dose distributions were analyzed and compared. Moreover, the Lifetime Attributable Risk (LAR) for developing radiation-induced bladder and bowel malignancies were assessed using a non-linear mechanistic model, assuming patient ages at treatment of 45, 50, 55 and 60 years. All 128 plans created were clinically acceptable. Risk of second bladder cancer reached 0.26% for HFRT (5 × 5 Gy) and 0.19% for CFRT (25 × 2 Gy) at the age of 45. Systematically higher risks were calculated for HFRT (5 × 5 Gy) as compared to CFRT (25 × 2 Gy), with 6 MV photons resulting in slightly increased LAR, as well. Similar or equal bowel cancer risks were calculated for all techniques and patient ages investigated (range 0.05-0.14%). This work contributes towards radiotherapy treatment protocol selection criteria for the preoperative irradiation of rectal carcinoma. However, more studies are needed to establish the associated radiation-induced risk of each RT protocol.
Identifiants
pubmed: 36143227
pii: jpm12091442
doi: 10.3390/jpm12091442
pmc: PMC9503780
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Pract Radiat Oncol. 2014 Jan-Feb;4(1):e15-20
pubmed: 24621427
Radiat Oncol. 2018 Dec 3;13(1):237
pubmed: 30509284
Phys Med. 2017 Oct;42:285-291
pubmed: 28189418
Lancet Oncol. 2021 Jan;22(1):29-42
pubmed: 33301740
Cancers (Basel). 2021 Dec 29;14(1):
pubmed: 35008308
Br J Surg. 2017 Feb;104(3):278-287
pubmed: 27802358
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645
J Neurosurg. 2000 Dec;93 Suppl 3:219-22
pubmed: 11143252
MMWR Morb Mortal Wkly Rep. 2020 Mar 13;69(10):253-259
pubmed: 32163384
Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1195-203
pubmed: 15990025
Phys Med. 2017 Oct;42:232-238
pubmed: 28242139
Radiat Oncol J. 2018 Jun;36(2):85-94
pubmed: 29983028
Theor Biol Med Model. 2010 Feb 11;7:4
pubmed: 20149259
Radiat Oncol J. 2012 Mar;30(1):27-35
pubmed: 23120741
Radiol Oncol. 2016 Feb 22;50(2):232-7
pubmed: 27247557
Oncotarget. 2017 Jun 27;8(26):42020-42029
pubmed: 28159930
Natl Vital Stat Rep. 2017 Aug;66(4):1-64
pubmed: 29155687
Radiat Oncol. 2016 Nov 10;11(1):149
pubmed: 27832799
PLoS One. 2019 Aug 16;14(8):e0221262
pubmed: 31419263
Int J Radiat Oncol Biol Phys. 2015 Sep 1;93(1):29-36
pubmed: 26163334
Phys Med. 2017 Oct;42:213-220
pubmed: 28236557
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Tech Innov Patient Support Radiat Oncol. 2019 Oct 15;11:14-21
pubmed: 32095545
PLoS One. 2019 Mar 7;14(3):e0213271
pubmed: 30845263
Med Phys. 2020 Jul;47(7):2805-2813
pubmed: 32266979
J Clin Oncol. 2012 Nov 1;30(31):3827-33
pubmed: 23008301
Am J Clin Oncol. 2007 Aug;30(4):333-9
pubmed: 17762431
Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):e353-62
pubmed: 22483697
Br J Surg. 2006 Oct;93(10):1215-23
pubmed: 16983741
Theor Biol Med Model. 2011 Jul 26;8:27
pubmed: 21791103
Oncol Lett. 2017 May;13(5):2971-2974
pubmed: 28521403
Semin Oncol. 2020 Feb;47(1):85-92
pubmed: 32147127
Colorectal Dis. 2014 Feb;16(2):O66-70
pubmed: 24148225
J Appl Clin Med Phys. 2021 Jul;22(7):103-109
pubmed: 34021692
Ther Adv Med Oncol. 2020 Feb 29;12:1758835920907537
pubmed: 32165928
J Radiat Oncol. 2018;7(1):77-84
pubmed: 29576860
Radiat Oncol. 2020 Nov 10;15(1):262
pubmed: 33172475
Oncotarget. 2016 Feb 2;7(5):6345-51
pubmed: 26621840
Cancers (Basel). 2022 May 13;14(10):
pubmed: 35626013
Lancet Oncol. 2017 Mar;18(3):336-346
pubmed: 28190762
Sci Rep. 2020 Jan 27;10(1):1220
pubmed: 31988348
Med Phys. 2017 Jul;44(7):3866-3874
pubmed: 28493609
Ann Oncol. 2017 Mar 1;28(3):535-540
pubmed: 27993790
Am Soc Clin Oncol Educ Book. 2014;:e57-67
pubmed: 24857148
Cancers (Basel). 2021 Apr 22;13(9):
pubmed: 33922197
J Clin Oncol. 2015 May 20;33(15):1640-6
pubmed: 25534376
Curr Treat Options Oncol. 2014 Sep;15(3):421-8
pubmed: 24915746
Int J Colorectal Dis. 2019 Dec;34(12):2171-2183
pubmed: 31745621
Radiother Oncol. 2005 Jul;76(1):43-7
pubmed: 16024115
Front Bioeng Biotechnol. 2020 May 07;8:306
pubmed: 32457880
Ann Oncol. 2016 May;27(5):834-42
pubmed: 26884592
Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):34-9
pubmed: 23265569
J Appl Clin Med Phys. 2020 Sep;21(9):82-89
pubmed: 32671989
J Gastrointest Oncol. 2019 Dec;10(6):1238-1250
pubmed: 31949945